NITROMED PUBLICATIONS

Papers | Abstracts

Angus, D.C., Linde-Zwirble, W.C., Tam, S,W., Ghali, J.K, Sabolinski, M.L.,Villagra,V.G., Winkelmayer, W.C., Worcel, M.  Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks with Heart Failure.  Circulation 112: 3745-3753 (2005)

Ranatunge, R.R., Earl, R.A., Garvey, D.S., Janero, D.R., Letts, L.G., Martino, A., Murty, M.G., Richardson, S.R., Schwalb, D.J., Young, D.V., Zemetseva, I.S.   3(2-Methoxytetrahydrofuran-2-yl)pyrazoles: A Novel Class of Potent, Selective Cyclooxygenase-2 (COX-2) Inhibitors. Bioorg Med. Chem. Letts. 14: 6049-6052 (2005)

Ellis, J.L., Augustyniak, M.E., Cochran, E.D.,  Earl, R.A., Garvey, D.S.,  Gordon, L.J., Janero, D.R., Khanapure, S.P., Letts, L.G., Melim, T.L., Murty, M.G., Schwalb, D.J., Shumway, M.J., Selig, W.M.,  Trocha, A.M., Young, D.V., Zemtseva, I.S. NMI-1182, a Gastroprotective Cyclooxygenase Inhibiting Nitric Oxide Donor. Inflammo. Pharmacology 12: 521-534 (2005)

Janero, D.R., Garvey, D.S.  Nitric Oxide Donors as Anti-platelet Agents for Thromboembolic Disorders:  Clinical Status and Therapeutic Prognosis.  Nitric Oxide Donors for Biological and Pharmaceutical Applications. Edited by P.G. Wong, T.B. Chi, N. Tanigushi, Wiley-VCH Verlas, pp 299-328 (2005)

Lin, C-E., Janero, D.R., Garvey, D.S.  Nitric Oxide (NO)-baased Molecular Strategies for Restenosis Therapy.  Expert Opinion on Therapeutic Patents.  15: 483-495 (2005)

Dhawan, V., Schwalb, D.J., Shumway, M.J., Warren, M.C., Wexler, R. S., Zemtseva, I.S.,  Zifcak, B.M., Janero, D.R.  Selective Nitros(yl)ation Induced in vivo by a Nitric Oxide-Donating Cyclooxygenase-2 Inhibitor: A NObonomic Analysis. Free Radical Biol. Med. 39: 1191-1207 (2005)

Young, D.V.,  Cochran, E.D., Dhawan, V., Earl, R.A., Ellis, J.L., Garvey, D.S.,  Janero, D.R.,  Khanapure, S.P.,  Letts, L.G.,. Melim, T.L., Murty, M.G., Shumway, M.J., Wey, S-J., Zemtseva, I.S., Selig. W.M. A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochemical Pharmacology  70: 1343–1351 (2005)

Khanapure, S.P., Augustyniak, M.E., Earl, R.A., Garvey, D.S., Letts, L.G., Martino, A.M., Murthy, M.G., Schwalb, D.J., Shumway, M.J., Trocha, A.M., Young, D.V.,  Zemtseva, I.S., Janero, D.R.  3-[4-(Methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone As a Potent and Orally Active Cyclooxygenase-2 (COX-2) Selective Inhibitor: Synthesis and Biological Evaluation.  J. Med. Chem. 48: 3930-3934 (2005)

Kernohan, A.F.B., McIntyre, M., Hughes, D.M., Murray, L., Tam, S.W., Worcel, M., Reid, J.L.  An Oral Yohimbine/L-Arginine Combination (NMI 861) for the Treatment of Male Erectile Dysfunction: Pharmacokinetic, Pharmacodynamic and Interaction Study with Intravenous Nitroglycerine in Healthy Male Volunteers, Br. J Clin. Pharmacol. 59: 85-93 (2005)

Ezawa, M., Garvey, D.S., Janero, D.R.,  Khanapure, S.P., Letts, L.G.; Martino, A., Ranatunge, R.R., Schwalb, D., Young. D.V.  Design of a Heteroaryl Modified 1,5-Disubstituted Pyrazole Cyclooxygenase-2 (COX-2) Selective Inhibitor.  Letters in Drug Design & Discovery 2: 184-193 (2005)

Taylor, A.L., Ziesche, S., Yancy, C., Carson, P., D’Agostino, R. Jr., , Ferdinand, K, Taylor, M., Adams, K., Sabolinski, M., Worcel, M., Cohn, J.N. and the A-HeFT Investigators. Combination of Isosorbide Dinitrate and Hydralazine in African Americans with Heart Failure. N. Engl. J. Med., 351: 2049-2057 (2004)

Janero, D.R., Bryan, N.S., Saijo, F., Dhawan, V., Schwalb, D.J., Warren, M.C., Feelisch. M. Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc. Natl. Acad. Sci. 101: 16958-16963 (2004)

Khanapure, S.P., Garvey, D.S. Use of Highly Reactive, Versatile and Air-Stable Palladium–phosphinous Acid Complex [(t-Bu)2P(OH)]2PdCl2 (POPd) as a Catalyst for the Optimized Suzuki-Miyaura Cross-coupling of Less Reactive Heteroaryl Chlorides and Arylboronic Acids. Tett. Letts. 45: 5283-5286 (2004)  

Lin, C-E., Garvey, D.S., Janero, D.R., Letts, L.G., Marek, P., Richardson, S.K., Shumway, M.J., Trocha, A.M., Young, D.V. The Combination of Paclitaxel and Nitric Oxide as a Potential Novel Treatment for the Prevention of Restenosis.  J. Med. Chem. 47: 2276-2282 (2004)

Ranatunge, R.R., Augustyniak, M., Bandarage, U.K., Earl, R.A., Ellis, J.L., Garvey, D.S.,  Janero, D.R., Letts, L.G., Martino, A.,  Murty, M.G., Richardson, S.K.,  Schroeder, J.D.,  Shumway, M.J., Tam, S.W.,  Trocha, A.M., Young, D.V.  Synthesis and Selective Cyclooxygenase-2 (Cox-2) inhibitory Activity of a Series of Novel Nitric Oxide Donor Containing Pyrazoles.  J. Med. Chem. 47: 2180-2193 (2004)

Ranatunge, R.R., Garvey, D.S., Janero, D.R., Letts, L.G., Martino, A.M., Murty, M.G., Richardson, S.K., Young, D.V., Zemtseva, I.S.  “Synthesis and Selective Cyclooxygenase-2 (COX-2) Inhibitory Activity of a Series of Novel Bicyclic Pyrazoles” Bioorg. Med. Chem. 12: 1357-1366 (2004)

Khanapure, S.P., Letts, L.G.  Perspectives and Clinical Significance of the Biochemical and Molecular Pharmacology of Eicosanoids.  Prostaglandins:  Biology and Chemistry of Prostaglandins and Related Eicosanoids.  Edited by P. B. Curtis-Prior, John Wiley & Sons, Ltd. 131-162 (2004)

Khanapure, S.P., Garvey, D.S., Young, D.V., Ezawa, M., Earl, R.A., Gaston, R.D., Fang, X., Murty, M., Martino, A., Shumway, M., Trocha, M., Marek, P.,  Tam, S.W.,  Janero, D.R., Letts. L.G.  Synthesis and Structure-Activity Relationship (SAR) of Novel, Highly Potent Metharyl and Methcycloalkyl Cyclooxygenase (COX-2) Selective Inhibitors.  J. Med. Chem. 46: 5484-5504 (2003)

Fang, X.,  Bandarage, U.K., Wang, T., Schroeder, J.D., Garvey, D.S.  First Examples of Oxidizing Aldehydes to Carboxylic Acids  in the Presence of a Tertiary Disulfide Functional Group:  Synthesis of Novel Diacid-disulfides.  Synlett. 489-492 (2003)

Labret, T., Herve, J.M., Gorny. P., Worcel, M., Botto, H. Efficacy and Safety of a Novel Combination of L-Arginine Glutamate and Yohimbine Hydrochloride: A New Oral Therapy for Erectile Dysfunction.   Eur Urol. 41:608-613 (2002)

Franciosa, J.A., Taylor, A.L., Cohn, J.N., Yancy, C.W., Ziesche, S., Olukotun, A., Ofili, E., Ferdinand, K., Loscalzo, J., Worcel, M. A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J. Card. Fail. 8: 128-135 (2002)

Meston, C.M., Worcel, M.  The Effects of Yohimbine plus L-Arginine Glutamate on Sexual Arousal in Postmenopausal Women with Sexual Arousal Ddisorder. Arch. Sex. Behav. 31: 323-332, (2002)

Taylor, A.L., Cohn, J.N., Worcel, M., Franciosa, J.A.  A-HeFT Investigators, African-American Heart Failure Trial. The African-American Heart Failure Trial: background, rationale and significance. J Natl. Med. Assoc. 94: 762-769 (2002)

Letts, G. L.  Cyclo-oxygenase-2 inhibition and exacerbation of myocardial dysfunction - protection with nitric oxide?    Br. J.  Pharmaco. 135: 1345-1346 (2002)

Lin, C-E., Richardson, S.K., Garvey, D.S. L-Cysteine as a Water-soluble Cation Scavenger in the Removal of the 2,4,6-Trimethoxybenzyl Group from Thiols. Te.t Let.  43: 4531-4533 (2002) 

Janero, D.R.  Nitric oxide and mammalian aging:  “surplus” and “deficit” as the two faces of a pharmaceutical currency for nitric oxide-modulator drugs.  Critical Reviews of Oxidative Stress and Aging: advances in basic science, diagnostics, and intervention.  R.G. Cutler and H. Rodriguez, editors. 1404-1417 (2002)

Tam, S.W., Worcel, M., Wyllie, M.  Yohimbine: A clinical review.  Pharmacol. Ther. 91: 215-243 (2001)

Janero, D.R.  Nutritional aspects of nitric oxide:  human health implications and therapeutic opportunities.  J. Nutr. 17: 896-903 (2001) 

Bandarage, U.K., Janero, D.R.  Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs): novel gastrointestinal-sparing prodrugs.  Med. Chem. Revs. 1: 57-70 (2001) 

Fang, X., Bandarage, U.K., Wang, T., Schroeder, J.D., Garvey, D.S.  First Examples of Oxidizing Secondary Alcohols to Ketones in the Presence of the Disulfide Functional Group:  Synthesis of Novel Diketone-disulfides. J. Org. Chem. 66: 4019-4021 (2001)

Young, D.V., Serebryanik, D., Janero, D.R., Tam, S.W.  Suppression of proliferation of human coronary artery smooth muscle cells by the nitric oxide donor, S-nitrosoglutathione, is cGMP independent.  Mol Cell Biol Research Comm 4: 32-36 (2000)

Janero, D.R., Ewing, J.F.  Nitric oxide and postangioplasty restenosis:  pathological correlates and therapeutic potential.  Free Radical Biol. Med.  29:1199-1221 (2000)

Bandarage, U.K., Chen, L., Fang, X., Garvey, D.S., Glavin, A., Janero, D.R., Letts, L.G., Mercer, G.J., Saha, J.K., Schroeder, J.D., Shumway, M.J., Tam, S.W.  Nitrosothiol Esters of Diclofenac: Synthesis and Pharmacological Characterization as Gastrointestinal-sparing Prodrugs.  J. Med. Chem.43: 4005-4016 (2000) 

Tam, S.W., Saha, J.K., Garvey, D.S., Schroeder, J.D., Shelekhin, T.E., Janero, D.R., Chen, L., Glavin, A., Letts, L.G.  Nitrosothiol-based NO-donors inhibit the gastrointestinal mucosal damaging actions of NSAIDs.  Inflammopharmacology 8: 81-88 (2000)

Janero, D.R.  Nitric oxide (NO)-related pharmaceuticals:  contemporary approaches to therapeutic NO modulation.  Free Radical Biol. Med.  28:1495-1506 (2000) 

Dong, Q., Fang, X., Schroeder, J.D., Garvey, D.S.  Practical, Efficient, Synthesis of b-amino Tertiary Thiols via Aminolysis Ring-opening of Thiiranes. Synthesis, 1106-1108 (1999)

Saenz de Tejada, I., Garvey, D.S., Schroeder, J.D., Shelekhin, T., Letts, L.G., Fernandez, A., Cuevas, B., Gabancho, S., Martinez, V., Angulo, J., Trocha, M., Marek, P., Cuevas, P., Tam, S.W.  Design and evaluation of nitrosylated a-adrenergic receptor antagonists as potential agents for the treatment of impotence.  J. Pharmacol. Exp. Ther. 290: 121-128 (1999)

Ewing, J.F., Janero, D.R    Specific S-nitrosothiol quantification as solution nitrite after vanadium(III) reduction and ozone-chemiluminescent detection.  Free Radical Biol. Med.  25: 621-628 (1998)

Ewing, J.F., Young, D.V., Janero, D.R., Garvey, D.S., Grinnell, T.A.  Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners.  J. Pharmacol. Exp. Ther.  283: 947-954 (1997) 

Weaver, C.E., Marek, P., Park-Chung, M., Tam, S.W., Farb, D.H.:  Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor.  Proc. Natl. Acad. Sci. USA  94: 10450-10454 (1997)

Ewing, J.F., Janero, D.R., Grinnell, T.A., Schroeder, J.D., Garvey, D.S.  Reactivity of nitrogen monoxide species with NADH:  implications for nitric oxide-dependent post-translational protein modification.  Arch. Biochem. Biophys.  343: 131-139 (1997) 

Ewing, J. F.  Detection of heme oxygenase-1 and -2 transcripts by Northern blot and in situ hybridization analysis.  Methods in Neurosciences  31 (Nitric Oxide Synthase: Characterization and Functional Analysis),  112-122 (1996)

Delyani, J.A.,  Tareck O., Nossuli, R. S., Thomas, G., Garvey, D.S., Lefer, A.M.  S-Nitrosylated Tissue Type Plasminogen Activator Protects Against Myocardial Ischemia-Reperfusion Injury:  Role of the Endothelium. J. Pharmacol. Exp. Ther.  279: 1174-1180 (1996)

Ewing, J.F., Janero, D.R.  Microplate superoxide dismutase assay employing a nonenzymatic superoxide generator.  Anal. Biochem.  232: 243-248 (1995)